BIO-TECHNE Corp (TECH) stock
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3040% above fair value
$72.80−0.02 (-0.03%)
Close on Nov 11, 2026Market cap $11.43BP/E 66.8Yield 0.44%
Bio-Techne r&d expenses
Research and development expenses are spending on new products and technology.
Bio-Techne's R&D Expenses for the twelve months ending Sep 30, 2026 was $96.87M, down 3.0% year over year. For fiscal 2026 it was $94.77M, down 4.8% from the year before. Over ten years it grew 7.7% a year on average. The highest annual figure on record is $99.50M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $94.77M | -4.8% |
| FY2025 | Jun 30, 2025 | $99.50M | +2.9% |
| FY2024 | Jun 30, 2024 | $96.66M | +4.5% |
| FY2023 | Jun 30, 2023 | $92.49M | +6.1% |
| FY2022 | Jun 30, 2022 | $87.14M | +23.4% |
| FY2021 | Jun 30, 2021 | $70.60M | +8.3% |
| FY2020 | Jun 30, 2020 | $65.19M | +4.5% |
| FY2019 | Jun 30, 2019 | $62.41M | +12.8% |
| FY2018 | Jun 30, 2018 | $55.33M | +3.4% |
| FY2017 | Jun 30, 2017 | $53.51M | +18.4% |
| FY2016 | Jun 30, 2016 | $45.19M | +10.6% |
| FY2015 | Jun 30, 2015 | $40.85M | +32.0% |
| FY2014 | Jun 30, 2014 | $30.95M | +5.8% |
| FY2013 | Jun 30, 2013 | $29.26M | +4.8% |
| FY2012 | Jun 30, 2012 | $27.91M | +7.4% |
| FY2011 | Jun 30, 2011 | $25.99M | +3.4% |
| FY2010 | Jun 30, 2010 | $25.12M | +6.6% |
| FY2009 | Jun 30, 2009 | $23.56M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $26.34M | +8.7% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $23.95M | -8.0% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $23.46M | -4.6% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $23.13M | -7.6% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $24.24M | +1.6% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $26.03M | +8.5% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $24.58M | -4.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $25.02M | +9.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $23.87M | -0.5% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $23.99M | +2.4% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $25.76M | +13.4% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $22.92M | +2.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $24.00M | +0.4% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $23.42M | +1.2% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $22.71M | +4.5% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $22.46M | +8.8% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $23.90M | +10.7% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $23.15M | +11.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $21.74M | +27.5% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $20.65M | +23.0% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $21.60M | +34.7% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $20.72M | +23.5% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $17.05M | +6.9% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $16.79M | +2.5% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $16.04M | -0.2% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $16.78M | +3.2% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $15.95M | +2.6% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $16.38M | +3.6% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $16.08M | +8.7% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $16.26M | +16.3% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $15.55M | +11.9% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $15.81M | +13.7% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $14.79M | +9.2% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $13.98M | +2.1% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $13.89M | +0.9% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $13.91M | +4.7% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $13.55M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $13.70M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $13.77M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $13.28M | – |
See a number that looks wrong?